This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Centene (CNC) Boosts Presence in Louisiana With Contract Win
by Zacks Equity Research
Centene's (CNC) latest contract renewal tends to improve health outcomes of Medicaid members of Louisiana.
Henry Schein (HSIC) Q4 Earnings Top Estimates, Margins Grow
by Zacks Equity Research
Robust performances by all three operating businesses drove Henry Schein's (HSIC) Q4 revenues.
Omnicell (OMCL) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Robust performance by the Product and Service segments is driving Omnicell's (OMCL) fourth-quarter top line.
Molina Healthcare (MOH) Q4 Earnings Beat on Higher Premiums
by Zacks Equity Research
Molina Healthcare (MOH) expects its 2022 business to witness reduced impacts from COVID. Strong Medicare and Medicaid performance is set to buoy results.
Molina (MOH) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Molina (MOH) delivered earnings and revenue surprises of 2.13% and 3.97%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Should SPDR Portfolio S&P 400 Mid Cap ETF (SPMD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPMD
Molina (MOH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Molina (MOH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Abbott's (ABT) Diabetes Arm Booms, Neuromodulation Sales Soft
by Zacks Equity Research
Even though COVID-19 case rates are surging in the United States and other geographies, Abbott is seeing growth in its consumer-facing businesses like nutrition, EPD and diabetes care.
Here's Why You Should Hold on to Tandem Diabetes (TNDM) for Now
by Zacks Equity Research
Investors are optimistic about Tandem Diabetes' (TNDM) t:slim X2 technology and greater use of Control-IQ technology.
Anthem (ANTM) Q4 Earnings Top Estimates
by Zacks Equity Research
Anthem (ANTM) delivered earnings and revenue surprises of 0.59% and 0.91%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Community Health (CYH) Unit Declares Pricing of Senior Notes
by Zacks Equity Research
Community Health's (CYH) wholly-owned arm exhibits monetary discretion by pricing senior notes to procure funds.
Molina Healthcare (MOH) Up 14.4% in 6 Months: Growth Ahead?
by Zacks Equity Research
Molina Healthcare (MOH) is likely to keep growing on the back of increasing membership and higher premium revenues.
Should Vanguard S&P MidCap 400 ETF (IVOO) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IVOO
Here's Why You Should Retain Cigna (CI) in Your Portfolio
by Zacks Equity Research
Cigna (CI) is well-poised for growth, attributable to solid segmental contributions, the continuous launch of affordable MA plans, a strong partner network and sufficient cash reserves.
Top Analyst Reports for Lowe's, Southern Company & Freeport-McMoRan
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Lowe's Companies, Inc. (LOW), The Southern Company (SO), and Freeport-McMoRan Inc. (FCX).
Here's Why Seasoned Investors are Retaining Mednax (MD)
by Zacks Equity Research
Banking on its strategic measures and a streamlined business, Mednax (MD) holds potential to reap benefits for investors.
Why Holding Anthem (ANTM) in Your Portfolio is a Prudent Move?
by Zacks Equity Research
Riding high on its strategic measures and a rising membership, Anthem (ANTM) holds prospects to reap benefits for investors.
Why Seasoned Investors are Retaining Community Health (CYH)
by Zacks Equity Research
Community Health Systems (CYH) is focused on making strategic acquisitions to boost its business through inorganic growth.
Here's Why You Should Retain Centene (CNC) in Your Portfolio
by Zacks Equity Research
Centene (CNC) is well poised for growth on the back of improving revenues, continuous expansion plans for the MA business and sufficient cash-generating abilities.
Humana (HUM) Cuts Medicare Enrollment Outlook, Tumbles 19.4%
by Zacks Equity Research
Humana (HUM) expects Group Medicare Advantage membership to remain flat in 2022, with competitive pricing possibly playing a crucial role.
Should iShares Core S&P MidCap ETF (IJH) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IJH
Molina Healthcare (MOH) Buys Cigna's TX Medicaid Contracts
by Zacks Equity Research
Molina Healthcare (MOH) purchases the Texas Medicaid contracts of Cigna to bolster its presence in the Texas region.
Why Should You Hold Universal Health (UHS) in Your Portfolio?
by Zacks Equity Research
Riding high on strategic measures and a solid solvency level, Universal Health (UHS) holds prospects to reap benefits for investors.
Here's Why You Should Retain UnitedHealth Group (UNH) Now
by Zacks Equity Research
UnitedHealth Group (UNH) is well-poised for growth on the back of solid top-line growth, expansion of service offerings through UnitedHealthcare and Optum units, and adequate cash flows.
Here's Why You Should Hold Onto Acadia Healthcare (ACHC) Now
by Zacks Equity Research
Acadia Healthcare (ACHC) is poised for growth due to higher revenues driven by solid demand for behavioral health services, multiple JVs with established healthcare systems and debt repayment efforts.